Cytosorbents Corp (CTSO)

Cytosorbents (CTSO) Stock Price & Analysis


CTSO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.03 - $4.59
Previous Close$3.32
Average Volume (3M)127.83K
Market Cap
Enterprise Value$141.07M
Total Cash (Recent Filing)$22.14M
Total Debt (Recent Filing)$18.25M
Price to Earnings (P/E)-4.4
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding43,157,879
10 Day Avg. Volume150,131
30 Day Avg. Volume127,835
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)3.90
Price to Sales (P/S)6.96
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-5.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.80
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda-4.64
Price Target Upside64.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $1.03 and its highest was $4.59 in the past 12 months.
    What is Cytosorbents Corp’s market cap?
    Currently, no data Available
    When is Cytosorbents Corp’s upcoming earnings report date?
    Cytosorbents Corp’s upcoming earnings report date is May 09, 2023 which is in 47 days.
      How were Cytosorbents Corp’s earnings last quarter?
      Cytosorbents Corp released its earnings results on Mar 09, 2023. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.165.
        Is Cytosorbents Corp overvalued?
        According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cytosorbents Corp pay dividends?
          Cytosorbents Corp does not currently pay dividends.
          What is Cytosorbents Corp’s EPS estimate?
          Cytosorbents Corp’s EPS estimate is -$0.13.
            How many shares outstanding does Cytosorbents Corp have?
            Cytosorbents Corp has 43,663,010 shares outstanding.
              What happened to Cytosorbents Corp’s price movement after its last earnings report?
              Cytosorbents Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Cytosorbents Corp?
                Among the largest hedge funds holding Cytosorbents Corp’s share is Royce & Associates LLC. It holds Cytosorbents Corp’s shares valued at N/A.


                  Cytosorbents Stock Smart Score

                  The Cytosorbents stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Cytosorbents Corp

                  CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Vivani Medical
                  Pulse Biosciences
                  Bionoid Pharma

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis